$CVM News

CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival

CEL-SCI Presents New Pre-Surgical Data From Its Phase 3 Trial Of Multikine At World Congress; Locally Advanced Primary Tumor With No Detectable Lymph Node Involved; Tumor Proportion Score Less Than 10%

CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

CEL-SCI Reports Fiscal Third Quarter 2026 Results

CEL-SCI Q3 EPS $(0.47) Up From $(1.36) YoY

CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study

CEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral Oncology

Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

CEL-SCI To Launch Phase 3 Confirmatory Study

CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

CEL-SCI Announces Closing of Offering

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

CEL-SCI Announces Dual-Track Strategy To Bring Multikine To Patients With Head And Neck Cancer Through Parallel Regulatory Pathways In The U.S. And Saudi Arabia

CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month

CEL-SCI Corporation Announces Pricing of Offering

CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia

CEL‑SCI To Sign Saudi Amarox Deal At BIO International Convention 2026, Advancing Multikine Commercialization In Saudi Arabia

CEL-SCI Reports Fiscal Second Quarter 2026 Results

CEL-SCI Q2 EPS $(0.67) Down From $(0.08) YoY